in combination with other cancer therapies, has shown a significant tumor response in patients with HER2-positive advanced gastric cancer. The trial results were presented today at the 2025 ASCO ...

HR+/HER2- breast cancer involves cells that test positive for hormone receptors and negative for HER2 proteins. It's the most ...

Disitamab vedotin already has a conditional approval in China for HER2-positive gastric cancer, and has been filed for HER2-positive bladder cancer on the strength of a pair of phase 2 trials.

Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, ...

Please provide your email address to receive an email when new articles are posted on . San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast ...

ramucirumab and paclitaxel in patients with previously treated HER2-positive gastric cancer,” said Kohei Shitara, M.D., Director of the Department of Gastrointestinal Oncology, National Cancer ...

Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer. All patients with breast ... knowledgeable and able to report to you the ...

Herceptin with chemotherapy improved OS and PFS in HER2-positive gastric cancers, but benefits decreased after ... 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium.

Taiwan needs to revamp research into stomach cancer and increase National Health Insurance (NHI) coverage for targeted ...

hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The Trop-2-directed antibody and topoisomerase inhibitor conjugate is approved for patients ...

Background: Variable rates of HER2 protein overexpression ... in patients with HER2-positive (fluorescence in situ hybridization [FISH] positive) ovarian cancer progressing under taxane ...